Caixa Empreender Awards 2016| Exogenus therapeutics (cohitec)
14
FEVEREIRO 2016 ADVANCED THERAPEUTICS THROUGH CELL ENGINEERING CAIXA EMPREENDER AWARD
-
Upload
caixa-geral-depositos -
Category
Business
-
view
220 -
download
2
Transcript of Caixa Empreender Awards 2016| Exogenus therapeutics (cohitec)
FEVEREIRO 2016
ADVANCED THERAPEUTICS THROUGH CELL ENGINEERING
CAIXA EMPREENDER AWARD
High probability of infection
High risk of amputations
Frequent treatments
Pain and impaired mobility
CARDIOVASCULAR DISEASE
DIABETESBED-BOUND
IMPAIRED BLOOD
CIRCULATION
COMPROMISED HEALING
CHRONIC WOUNDSDo not heal for more
than 6 weeks
PROBLEM & NEED
Source: MedMarket Diligence, 2013
50 million chronic wound patients worldwide
Standard care is not efficient in healing 70%
of these wounds
THE PROBLEM WE ARE ADDRESSING
PROBLEM & NEED
Market growth driven by increased incidence of obesity and diabetes combined with an aging population.
Umbilical Cord Blood
CHALLENGE: Use of Stem Cells components for the treatment of Chronic Wounds
TECHNOLOGY
External manipulation toincrease the activity
Non-Cellular Product with High
Therapeutic Activity
EXO-101
“I have trouble believing that stem cells will survive the harsh environment of the wound.”Professor Martins-Green, Board of Directors of the Wound Healing Society
In collaboration with
Complete healing in 15 days
Accelerates Healing
Promotes Vascularization
Stimulates Skin Growth
CONTROL
EXO-101
DAY 0 DAY 10
TECHNOLOGY VALIDATION
100% mice responded to treatment
Wound size half of control after 10 days
EXO-101
50% improvement when compared
with control treatment
Significant improvement from DAY 2
Signigficant improvement from DAY 6
TECHNOLOGY DIFFERENTIATION
MAJOR ACHIEVEMENTS
EXOGENUS THERAPEUTICS founded in June 2015
€100K pre-seed investment by Caixa Capital
Young Entrepreneur Award 2015 by ANJE
€800K seed investment by Caixa Capital and Change Partners
MILESTONES STATUS
Business Plan
Seed Fund
Development of pre-clinical strategy
Product Development
Seek non-dilutive funding
Developing at the right pace
ROADMAP & FUTURE MILESTONES
2015 2016 2017 2018 2019 2020
SEED FUND
€900K €1.2M
Approval of Clinical Trial
Product formulation
GLP animal tests
GMP production
IND submission
Funding Round A
POSSIBLE EXIT 1 Results Clinical Trial Phase I/II
POSSIBLE EXIT 2
€7.5M
Phase I Clinical Trial
Phase II Clinical TrialEquity + Convertible Note
Cap Table:Founders – 54%Investors – 36%
ESOP – 10%
BOARD MEMBERS
David MaltaJoana Correia
Founder
Pedro Vilarinho Pedro Pinheiro
TEAM & PARTNERS
Luísa Marques, MBA
Chief Operations Officer
Ricardo Neves, PhD
Scientific Consultant
Joana Simões Correia, PhD
Chief Scientific Officer
Renato Cardoso, PhD
Head of Laboratory
Your life, back in your hands.
